1773 related articles for article (PubMed ID: 8106625)
1. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation.
Bertagna X; Escourolle H; Pinquier JL; Coste J; Raux-Demay MC; Perles P; Silvestre L; Luton JP; Strauch G
J Clin Endocrinol Metab; 1994 Feb; 78(2):375-80. PubMed ID: 8106625
[TBL] [Abstract][Full Text] [Related]
2. Pituitary-adrenal response to RU 486 in man.
Bertagna X
Psychoneuroendocrinology; 1997; 22 Suppl 1():S51-5. PubMed ID: 9264147
[TBL] [Abstract][Full Text] [Related]
3. RU 486 prevents the acute effects of cortisol on glucose and leucine metabolism.
Garrel DR; Moussali R; De Oliveira A; Lesiège D; Larivière F
J Clin Endocrinol Metab; 1995 Feb; 80(2):379-85. PubMed ID: 7888013
[TBL] [Abstract][Full Text] [Related]
4. The antiglucocorticoid and antiprogestin steroid RU 486 suppresses the adrenocorticotropin response to ovine corticotropin releasing hormone in man.
Laue L; Chrousos GP; Loriaux DL; Barnes K; Munson P; Nieman L; Schaison G
J Clin Endocrinol Metab; 1988 Feb; 66(2):290-3. PubMed ID: 2828406
[TBL] [Abstract][Full Text] [Related]
5. Effects of the glucocorticoid antagonist RU 486 on pituitary-adrenal function in patients with anorexia nervosa and healthy volunteers: enhancement of plasma ACTH and cortisol secretion in underweight patients.
Kling MA; Demitrack MA; Whitfield HJ; Kalogeras KT; Listwak SJ; DeBellis MD; Chrousos GP; Gold PW; Brandt HA
Neuroendocrinology; 1993 Jun; 57(6):1082-91. PubMed ID: 8232766
[TBL] [Abstract][Full Text] [Related]
6. The new steroid analog RU 486 inhibits glucocorticoid action in man.
Bertagna X; Bertagna C; Luton JP; Husson JM; Girard F
J Clin Endocrinol Metab; 1984 Jul; 59(1):25-8. PubMed ID: 6327758
[TBL] [Abstract][Full Text] [Related]
7. Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects.
Laue L; Lotze MT; Chrousos GP; Barnes K; Loriaux DL; Fleisher TA
J Clin Endocrinol Metab; 1990 Dec; 71(6):1474-80. PubMed ID: 2172280
[TBL] [Abstract][Full Text] [Related]
8. Effects of repetitive administration of corticotropin-releasing hormone combined with lysine vasopressin on plasma adrenocorticotropin and cortisol levels in secondary adrenocortical insufficiency.
Fukata J; Usui T; Tsukada T; Nakai Y; Koh T; Ishihara T; Tanaka I; Uchida K; Yoshimasa T; Nakano R
J Clin Endocrinol Metab; 1990 Dec; 71(6):1624-31. PubMed ID: 2172283
[TBL] [Abstract][Full Text] [Related]
9. Chronic brain glucocorticoid receptor blockade enhances the rise in circadian and stress-induced pituitary-adrenal activity.
van Haarst AD; Oitzl MS; Workel JO; de Kloet ER
Endocrinology; 1996 Nov; 137(11):4935-43. PubMed ID: 8895366
[TBL] [Abstract][Full Text] [Related]
10. The effects of the acute administration of RU 486 on dietary fat preference in fasted lean and obese men.
Kramlik SK; Altemus M; Castonguay TW
Physiol Behav; 1993 Oct; 54(4):717-24. PubMed ID: 8248349
[TBL] [Abstract][Full Text] [Related]
11. RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day.
Gaillard RC; Riondel A; Muller AF; Herrmann W; Baulieu EE
Proc Natl Acad Sci U S A; 1984 Jun; 81(12):3879-82. PubMed ID: 6328529
[TBL] [Abstract][Full Text] [Related]
12. The endocrine effects of long-term treatment with mifepristone (RU 486).
Lamberts SW; Koper JW; de Jong FH
J Clin Endocrinol Metab; 1991 Jul; 73(1):187-91. PubMed ID: 1646217
[TBL] [Abstract][Full Text] [Related]
13. Effects of ovine corticotropin-releasing hormone on adrenocorticotropin secretion in the absence of glucocorticoid feedback inhibition in man.
Debold CR; Jackson RV; Kamilaris TC; Sheldon WR; Decherney GS; Island DP; Orth DN
J Clin Endocrinol Metab; 1989 Feb; 68(2):431-7. PubMed ID: 2537333
[TBL] [Abstract][Full Text] [Related]
14. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome.
Bertagna X; Bertagna C; Laudat MH; Husson JM; Girard F; Luton JP
J Clin Endocrinol Metab; 1986 Sep; 63(3):639-43. PubMed ID: 3734034
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of the ACTH response to human CRH by pretreatment with the antiglucocorticoid RU-486.
Hermus AR; Pieters GF; Pesman GJ; Smals AG; Benraad TJ; Kloppenborg PW
Eur J Clin Pharmacol; 1987; 31(5):609-11. PubMed ID: 3030764
[TBL] [Abstract][Full Text] [Related]
16. The combined corticotropin-releasing hormone/lysine vasopressin test discloses a corticotroph phenotype.
Bertagna X; Coste J; Raux-Demay MC; Letrait M; Strauch G
J Clin Endocrinol Metab; 1994 Aug; 79(2):390-4. PubMed ID: 8045953
[TBL] [Abstract][Full Text] [Related]
17. Effects of carbamazepine on pituitary-adrenal function in healthy volunteers.
Perini GI; Devinsky O; Hauser P; Gallucci WT; Theodore WH; Chrousos GP; Gold PW; Kling MA
J Clin Endocrinol Metab; 1992 Feb; 74(2):406-12. PubMed ID: 1309836
[TBL] [Abstract][Full Text] [Related]
18. Transient inhibition of RU 486 antiglucocorticoid action by dexamethasone.
Raux-Demay MC; Pierret T; Bouvier d'Yvoire M; Bertagna X; Girard F
J Clin Endocrinol Metab; 1990 Jan; 70(1):230-3. PubMed ID: 2152931
[TBL] [Abstract][Full Text] [Related]
19. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome.
Demitrack MA; Dale JK; Straus SE; Laue L; Listwak SJ; Kruesi MJ; Chrousos GP; Gold PW
J Clin Endocrinol Metab; 1991 Dec; 73(6):1224-34. PubMed ID: 1659582
[TBL] [Abstract][Full Text] [Related]
20. Reliability of hormonal levels for assessing the hypothalamic-pituitary-adrenocortical system in clinical pharmacology.
Coste J; Strauch G; Letrait M; Bertagna X
Br J Clin Pharmacol; 1994 Nov; 38(5):474-9. PubMed ID: 7893592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
